ArticleMultiple sclerosis (Houndmills, Basingstoke, England)2020
Pathological findings in central nervous system demyelination associated with infliximab.
Article in Multiple sclerosis (Houndmills, Basingstoke, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 20 citations in OpenAlex.
- Article
- Inflammatory bowel disease therapies and demyelinating diseases: a practical guide to therapeutic benefit and risk.Journal of Crohn's & colitis · 2026Review
- Tumefactive Demyelinating Lesion Induced by Infliximab in a Patient With Rheumatoid Arthritis: A Case Report.Clinical case reports · 2025Article
- Golimumab therapy-induced isolated myelitis in a Behcet's disease patient: a case report.Annals of medicine and surgery (2012) · 2023Article
- Long-term clinical, imaging and cognitive outcomes association with MS immunopathology.Annals of clinical and translational neurology · 2023Observational
- Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2023Review
- Tissue donations for multiple sclerosis research: current state and suggestions for improvement.Brain communications · 2022Review
- Neuroinflammation Associated With Tumor Necrosis Factor-α Inhibitor Exposure.Neurology. Clinical practice · 2021Article
Corrections and comments
- Commented on by
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundTumor necrosis factor alpha (TNF-alpha) inhibitors, such as infliximab, are commonly used to treat rheumatoid arthritis (RA) and other immune-mediated disorders.
objectiveTo determine whether infliximab-associated central nervous system (CNS) demyelination can be differentiated from multiple sclerosis (MS).
methodsWe present a case of pathologically proven CNS demyelination in a patient treated with infliximab and describe clinical-radiographic-neuropathological findings. Putative mechanisms of TNF-alpha inhibitor-associated CNS demyelination are described. RESULTS AND
conclusionInfliximab treatment is associated with CNS inflammatory demyelinating activity, which is histopathologically indistinguishable from MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.